These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 30900911)

  • 41. Development of Interferon-Free, Direct-Acting Antivirals Treatment for Japanese Patients with Chronic Hepatitis C Infection and Chronic Kidney Disease.
    Atsukawa M; Kondo C; Kawano T; Okubo T; Arai T; Nakagawa-Iwashita A; Itokawa N; Iwakiri K
    J Nippon Med Sch; 2021 Jun; 88(3):163-170. PubMed ID: 33692289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postsustained Virological Response Management in Hepatitis C Patients.
    Masetti C; Lleo A; Colombo M; Colombo M; Aghemo A
    Semin Liver Dis; 2020 Aug; 40(3):233-239. PubMed ID: 32107758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients.
    Lybeck C; Brenndörfer ED; Sällberg M; Montgomery SM; Aleman S; Duberg AS
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):506-513. PubMed ID: 30461522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Diagnosis and treatment strategies of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antiviral drugs].
    Gao X; Ji FP
    Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):827-830. PubMed ID: 33105926
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HCV targeting of patients with cirrhosis.
    Ferenci P; Kozbial K; Mandorfer M; Hofer H
    J Hepatol; 2015 Oct; 63(4):1015-22. PubMed ID: 26100497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis.
    Ponziani FR; Putignani L; Paroni Sterbini F; Petito V; Picca A; Del Chierico F; Reddel S; Calvani R; Marzetti E; Sanguinetti M; Gasbarrini A; Pompili M
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1301-1311. PubMed ID: 30345704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
    Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
    World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful treatment of hepatitis C, genotype 3, with sofosbuvir/ledipasvir in decompensated cirrhosis complicated by mixed cryoglobulinaemia.
    Flemming JA; Lowe CE
    BMJ Case Rep; 2016 Jun; 2016():. PubMed ID: 27284099
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcome of antiviral therapy in Egyptian Hepatitis C Virus (HCV) genotype 4 patients with advanced liver fibrosis.
    el-Khattib AA; Abdelhakam SM; Ghoraba DM; Ibrahim WA; Sayed MM
    Eur J Intern Med; 2012 Jan; 23(1):e34-5. PubMed ID: 22153547
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort).
    Gentile I; Scotto R; Coppola C; Staiano L; Amoruso DC; De Simone T; Portunato F; De Pascalis S; Martini S; Macera M; Viceconte G; Tosone G; Buonomo AR; Borgia G; Coppola N
    Hepatol Int; 2019 Jan; 13(1):66-74. PubMed ID: 30523552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A; Venkataraman J
    Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review.
    Fehily SR; Papaluca T; Thompson AJ
    Semin Liver Dis; 2019 Jul; 39(3):341-353. PubMed ID: 31041785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.
    Gonzalez HC; Duarte-Rojo A
    Curr Gastroenterol Rep; 2016 Jul; 18(7):32. PubMed ID: 27177638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.
    Poveda E; Vispo E; Barreiro P; de Mendoza C; Labarga P; Fernández-Montero JV; Martin-Carbonero L; Soriano V
    Antivir Ther; 2012; 17(3):571-5. PubMed ID: 22293607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of chronic hepatitis C in patients with cirrhosis.
    Chen T; Terrault N
    Curr Opin Gastroenterol; 2016 May; 32(3):143-51. PubMed ID: 27023162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.
    Gimeno-Ballester V; Buti M; San Miguel R; Riveiro M; Esteban R
    J Viral Hepat; 2017 Nov; 24(11):904-916. PubMed ID: 27925386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent Advances in Antiviral Therapy for Chronic Hepatitis C.
    Tamori A; Enomoto M; Kawada N
    Mediators Inflamm; 2016; 2016():6841628. PubMed ID: 27022210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies.
    Ramos-Rincon JM; Pinargote-Celorio H; de Mendoza C; Ramos-Belinchón C; Barreiro P; Gómez-Gallego F; Corral O; Soriano V
    J Viral Hepat; 2022 Sep; 29(9):777-784. PubMed ID: 35643914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.